Drugs with anticholinergic properties: a current perspective on use and safety.

abstract：:Introduction: Cutaneous T-cell lymphomas (CTCL) are rare non-Hodgkin lymphomas of skin-homing T-cells that initially or mainly manifest cutaneously. Treatment of CTCL is challenging given the disease states' varying presentation and prognosis. Systemic treatment options often lack comparative evidence and have relativ...

journal_title：Expert opinion on drug safety

authors： Afifi S,Mohamed S,Zhao J,Foss F

更新日期：2019-09-01 00:00:00

abstract：:Methotrexate is a commonly prescribed antineoplastic and immune modulating compound that has gained wide acceptance in the management of rheumatoid arthritis, psoriasis, sarcoidosis and a number of neoplastic disorders. Although generally considered safe and easy to use, methotrexate has been associated with a number ...

journal_title：Expert opinion on drug safety

authors： Lateef O,Shakoor N,Balk RA

更新日期：2005-07-01 00:00:00

abstract：INTRODUCTION:Paliperidone, the major active metabolite of risperidone, is a second-generation antipsychotic that has been developed as an extended-release (ER) oral formulation and a long-acting injectable paliperidone palmitate (PP) formulation. Paliperidone has demonstrated efficacy in the reduction of acute schizoph...

journal_title：Expert opinion on drug safety

authors： Mauri MC,Reggiori A,Paletta S,Di Pace C,Altamura AC

更新日期：2017-03-01 00:00:00

abstract：:Introduction: Psoriasis is a chronic inflammatory systemic disease that affects 2% of the population and is associated with an important physical and physiological burden. About 0.5-2% of psoriatic cases onset during the pediatric age range, and often it's not diagnosed until adulthood. Adalimumab is an antitumor necr...

journal_title：Expert opinion on drug safety

authors： Zangrilli A,Bavetta M,Bianchi L

更新日期：2020-04-01 00:00:00

abstract：:Introduction: The use of testosterone therapy (TTh) in men with prostate cancer (PCa) is relatively new, and controversial, due to the longstanding maxim that TTh is contraindicated in men with PCa. Scientific advances have prompted a reevaluation of the potential role for TTh in men with PCa, particularly as TTh has ...

journal_title：Expert opinion on drug safety

authors： Morgentaler A,Caliber M

更新日期：2019-11-01 00:00:00

abstract：BACKGROUND:E-detailing can be best described as the use of information technology in the field of pharmaceutical detailing. It is becoming highly popular among pharmaceutical companies because it maximizes the time of the sales force, cuts down the cost of detailing and increases physician prescribing. Thus, the applic...

journal_title：Expert opinion on drug safety

authors： Montoya ID

更新日期：2008-11-01 00:00:00

abstract：:In a very short time, COX-2 enzyme inhibitors have gone from the darlings to the pariahs of the pharmaceutical industry. These drugs were developed based on the hypothesis whereby selective inhibition of the COX enzyme would lead to reduction in pain and inflammation without associated gastrointestinal and bleeding ri...

journal_title：Expert opinion on drug safety

authors： Brophy JM

更新日期：2005-11-01 00:00:00

abstract：:Osteonecrosis of the jaw is a new disease, partly caused by bisphosphonates. It is commonly assumed that the bisphosphonates somehow cause cell death (osteocyte necrosis) within the jawbone, which makes it prone to chronic infection. In this article, an alternative pathogenetic theory is suggested, based on the normal...

journal_title：Expert opinion on drug safety

authors： Aspenberg P

更新日期：2006-11-01 00:00:00

abstract：INTRODUCTION:A number of new biological immune modulators have become available as treatments for inflammatory diseases over the past two decades. Most prominent among them are TNF-α inhibitors (TNFi) which have been available in the clinic since the late 1990s. TNFi have demonstrated efficacy in various rheumatologic ...

journal_title：Expert opinion on drug safety

authors： Yang H,Kavanaugh A

更新日期：2014-01-01 00:00:00

abstract：INTRODUCTION:The antimalarial drug hydroxychloroquine (HCQ) is widely used to treat various rheumatic diseases. Many autoimmune diseases occur in women of child-bearing age who may become pregnant while on therapy, which raises concerns regarding the teratogenicity of HCQ and its effect on the outcome of the pregnancy....

journal_title：Expert opinion on drug safety

authors： Abarientos C,Sperber K,Shapiro DL,Aronow WS,Chao CP,Ash JY

更新日期：2011-09-01 00:00:00

abstract：INTRODUCTION:Osteoarthritis (OA) is the most common form of arthritis and is a major cause of disability, especially in people ≥ 45 years old. Several international societies recommend the use of both acetaminophen and non-steroidal anti-inflammatory drugs (NSAIDs) to alleviate OA pain. However, patients with OA often ...

journal_title：Expert opinion on drug safety

authors： Richette P,Latourte A,Frazier A

更新日期：2015-08-01 00:00:00

abstract：:This review aims to give an updated overview of the worldwide situation of off-label and unlicensed drug use in the paediatric field, also taking into account the safety of this kind of treatment. A Medline and Embase search was performed between 1990 and 2006 and a total of 52 studies were identified and included in ...

journal_title：Expert opinion on drug safety

authors： Cuzzolin L,Atzei A,Fanos V

更新日期：2006-09-01 00:00:00

abstract：BACKGROUND:Critically ill patients receiving parenteral drugs are at an increased risk of exposure to various excipients administered simultaneously and at increased amounts. Hence, we carried out the present study. RESEARCH DESIGN AND METHODS:Patients admitted in the adult, pediatric, and neonatal intensive care unit...

journal_title：Expert opinion on drug safety

authors： Sridharan K,Hasan HM,Al Jufairi M,Al Daylami A,Al Ansari E,Qader AM,Pasha SAA

更新日期：2020-12-01 00:00:00

abstract：INTRODUCTION:During the last decade, the development of small molecule inhibitors of Janus kinases (JAKi) contributed to revolutionize the therapeutic landscape of myelofibrosis (MF). JAKi proved to be effective in controlling disease-related symptoms and splenomegaly with remarkable inter-drug variability. However, in...

journal_title：Expert opinion on drug safety

authors： Coltro G,Vannucchi AM

更新日期：2020-12-27 00:00:00

abstract：INTRODUCTION:There is now 16 years' worth of established results of various trials demonstrating the bortezomib efficiency in the treatment of multiple myeloma. Over this time, the introduction of bortezomib has been a major break through in the treatment of multiple myeloma. Bortezomib can be administered in the outpa...

journal_title：Expert opinion on drug safety

authors： Cengiz Seval G,Beksac M

更新日期：2018-09-01 00:00:00

abstract：:Methadone is an interesting analgesic for multiple reasons. The unique properties of the agent, low cost and widespread availability have led to increases in methadone prescribing. Despite advantages, methadone is challenging to work with, particularly in patients with high opioid requirements. Recent concerns regardi...

journal_title：Expert opinion on drug safety

authors： Swegle JM,Wensel DD

更新日期：2008-01-01 00:00:00

abstract：INTRODUCTION:The introduction of pneumococcal conjugate vaccines (PCVs) in the routine immunization program has resulted in a significant decline in invasive pneumococcal diseases (IPD) around the world. Preterm infants are a special group at a high risk of invasive infection by encapsulated bacteria. However, their sl...

journal_title：Expert opinion on drug safety

authors： López-Sanguos C,Rivero Calle I,Rodriguez Tenreiro C,Raguindin PF,Martinón-Torres F

更新日期：2019-04-01 00:00:00

abstract：INTRODUCTION:Dolutegravir (DGV) is the newest integrase inhibitor approved for the treatment of HIV-1 infection in both treatment-naive and experienced adults and adolescents. This article reviews the safety of DGV for the treatment of HIV-1 infection. AREAS COVERED:The PubMed database was searched using the keywords ...

journal_title：Expert opinion on drug safety

authors： Keeshin SW,Feinberg J

更新日期：2015-01-01 00:00:00

abstract：INTRODUCTION:Patients with end-stage renal disease (ESRD) are considered at higher risk of influenza-related complications and are listed worldwide among the subjects for whom yearly influenza vaccination is strongly recommended. However, influenza vaccination coverage of patients with ESRD is significantly lower than ...

journal_title：Expert opinion on drug safety

authors： Principi N,Esposito S,ESCMID Vaccine Study Group (EVASG).

更新日期：2015-08-01 00:00:00

abstract：BACKGROUND:The abuse and diversion of pharmacological agents with CNS mechanisms of action is an important concern from governmental, regulatory, public health and safety perspectives. In recent years, there have been an increased number of reports concerning the abuse and diversion of quetiapine in forensic population...

journal_title：Expert opinion on drug safety

authors： Tcheremissine OV

更新日期：2008-11-01 00:00:00

abstract：BACKGROUND:To perform an international comparison and analysis of celecoxib spontaneous adverse event reports (AERs) from Canada, Australia and the United States, focusing on gastrointestinal, renal and cardiovascular events. This study also examined concomitant medicines use which may have potentiated the risk of the ...

journal_title：Expert opinion on drug safety

authors： Baselyous Y,De Cocinis M,Ibrahim M,Kalra A,Yacoub R,Ahmed R

更新日期：2019-03-01 00:00:00

abstract：:This meeting was convened to encourage the incorporation of empirical and mechanism-based pharmacokinetic/pharmacodynamic (PK/PD) modelling into safety pharmacology to improve the predictability of nonclinical investigations for human outcomes. These technologies make use of mathematical expressions relating measured ...

journal_title：Expert opinion on drug safety

authors： Cavero I

更新日期：2007-07-01 00:00:00

abstract：:Stroke is a common cause for morbidity and mortality, causing substantial economic costs. Because thrombosis plays a key role in the pathogenesis of ischaemic stroke, heparins, platelet inhibitors and anticoagulants have been used in stroke management. There were high hopes that patients might benefit from the use of ...

journal_title：Expert opinion on drug safety

authors： Kiphuth IC,Köhrmann M,Huttner HB,Schellinger PD

更新日期：2009-09-01 00:00:00

abstract：INTRODUCTION:Development of new drugs in oncology may have implications for cardiovascular risk. This report describes some aspects of our growing knowledge in the area of evaluating benefit-risk and may be of direct importance to scientists working in drug discovery and development. AREAS COVERED:This report of webin...

journal_title：Expert opinion on drug safety

authors： Braddock M,Heilbraun J,Mendzelevski B

更新日期：2013-09-01 00:00:00

abstract：INTRODUCTION:Acne is a common skin condition of the pilosebaceous units that affects the young and old, ranges from moderate to severe and can be treated with an array of options. Topical retinoids are the initial treatment for acne due to their ability to treat comedones, the starting point of acne. AREAS COVERED:Taz...

journal_title：Expert opinion on drug safety

authors： Smith JA,Narahari S,Hill D,Feldman SR

更新日期：2016-01-01 00:00:00

abstract：INTRODUCTION:Conventional systemic therapies for psoriasis are associated with serious toxicities that can limit long-term use. In recent years, biological therapies have offered the possibility of long-term therapy with improved safety and efficacy for the treatment of psoriasis. Biological therapies can be classified...

journal_title：Expert opinion on drug safety

authors： Talamonti M,Spallone G,Di Stefani A,Costanzo A,Chimenti S

更新日期：2011-03-01 00:00:00

abstract：BACKGROUND:Ximelagatran, the first oral agent in the new class of direct thrombin inhibitors, was withdrawn from the market due to increased rates of liver enzyme elevations in long-term treatments. Despite intensive pre clinical investigations the cellular mechanisms behind the observed hepatic effects remain unknown....

journal_title：Expert opinion on drug safety

authors： Ainscow EK,Pilling JE,Brown NM,Orme AT,Sullivan M,Hargreaves AC,Cooke EL,Sullivan E,Carlsson S,Andersson TB

更新日期：2008-07-01 00:00:00

abstract：:Bone morphogenetic proteins (BMPs) have been extensively studied since the discovery of agents within bone that could induce bone formation at ectopic sites by Urist in the 1960s. Extensive preclinical research has been carried out showing the efficacy of these products in promoting bone healing. Clinical trials are e...

journal_title：Expert opinion on drug safety

authors： Harwood PJ,Giannoudis PV

更新日期：2005-01-01 00:00:00

abstract：INTRODUCTION:Despite the significant advances in the pharmacological and interventional management of patients with cardiovascular disease (CVD) over the last decades, cardiovascular mortality remains the leading cause of death. Large randomized clinical trials have investigated the efficacy and safety of different ant...

journal_title：Expert opinion on drug safety

authors： Romano S,Buccheri S,Mehran R,Angiolillo DJ,Capodanno D

更新日期：2018-10-01 00:00:00

abstract：INTRODUCTION:In the past two decades, the number of women with autoimmune and inflammatory diseases experiencing a pregnancy has significantly increased in parallel with the enormous advances in the diagnosis and management of these disorders. However, information regarding the safety of immunosuppressive agents comes ...

journal_title：Expert opinion on drug safety

authors： Gerosa M,Meroni PL,Cimaz R

更新日期：2014-12-01 00:00:00